Clinical Trials Directory

Trials / Conditions / Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

19 registered clinical trials studyying Relapsed/Refractory Acute Myeloid Leukemia — 7 currently recruiting.

StatusTrialSponsorPhase
RecruitingEvaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
NCT06714591
SystImmune Inc.Phase 1
Not Yet RecruitingCD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
NCT06696846
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 1
RecruitingStudy of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06549790
Nerviano Medical SciencesPhase 1
RecruitingSafety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
NCT06541444
Base Therapeutics (Shanghai) Co., Ltd.EARLY_Phase 1
RecruitingSafety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
NCT06541405
Base Therapeutics (Shanghai) Co., Ltd.EARLY_Phase 1
RecruitingClinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid
NCT06084819
Chinese PLA General HospitalPhase 2
WithdrawnStudy Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refrac
NCT03904069
AmgenPhase 1
UnknownClinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
NCT05722171
PersonGen BioTherapeutics (Suzhou) Co., Ltd.EARLY_Phase 1
UnknownUTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
NCT05731219
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Phase 1
CompletedLILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
NCT05518357
Hebei Yanda Ludaopei HospitalPhase 1
Enrolling By InvitationLong-Term Follow-up Study
NCT05332054
Caribou Biosciences, Inc.—
UnknownA Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy o
NCT05061147
Maxinovel Pty., Ltd.Phase 1 / Phase 2
CompletedA Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
NCT03886831
Prelude TherapeuticsPhase 1
TerminatedEfficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R
NCT03504410
Cornerstone PharmaceuticalsPhase 3
TerminatedArsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT03318016
University of Colorado, DenverPhase 1
Active Not RecruitingStudy Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukem
NCT03190278
Cellectis S.A.Phase 1
CompletedA Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patie
NCT02665143
Yale UniversityPhase 2
UnknownDecitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Trans
NCT01806116
The First Affiliated Hospital of Soochow UniversityPhase 4
No Longer AvailableUS Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT05627466
Gilead Sciences—